Path ID: DB00810_MESH_D010300_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D001712 | biperiden | Drug |
| UniProt:P11229 | Muscarinic acetylcholine receptor M1 | Protein |
| GO:0007271 | synaptic transmission, cholinergic | BiologicalProcess |
| HP:0100022 | Abnormality of movement | PhenotypicFeature |
| MESH:D010300 | Parkinson’s disease | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Biperiden | NEGATIVELY REGULATES | Muscarinic Acetylcholine Receptor M1 |
| Muscarinic Acetylcholine Receptor M1 | POSITIVELY REGULATES | Synaptic Transmission, Cholinergic |
| Synaptic Transmission, Cholinergic | POSITIVELY CORRELATED WITH | Abnormality Of Movement |
| Abnormality Of Movement | MANIFESTATION OF | Parkinson’S Disease |
Comment: In Parkinson’s disease, there is imbalance between levels of acetylcholine and dopamine, where increased levels of acetylcholine and degeneration of dopaminergic pathways are observed. Therefore, muscarinic antagonists such as biperiden block central cholinergic activity and balancing out neurotransmitters in the brain (https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects). Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
Reference: